On the public citation graph

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

https://doi.org/10.1093/infdis/jiv082
0 signed · 244 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.vaccine.2011.06.094openalex-snapshot
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
inferredcites →https://doi.org/10.1016/j.vaccine.2011.07.023openalex-snapshot
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
inferredcites →https://doi.org/10.1016/j.vaccine.2013.05.075openalex-snapshot
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles
inferredcites →https://doi.org/10.1016/s0140-6736(07)61687-0openalex-snapshot
Dengue
inferredcites →https://doi.org/10.1016/s0140-6736(12)61428-7openalex-snapshot
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
inferredcites →https://doi.org/10.1016/s0140-6736(14)61060-6openalex-snapshot
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
inferredcites →https://doi.org/10.1016/s1473-3099(14)70811-4openalex-snapshot
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
inferredcites →https://doi.org/10.1038/nature12060openalex-snapshot
The global distribution and burden of dengue
inferredcites →https://doi.org/10.1056/nejmoa1411037openalex-snapshot
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
inferredcites →https://doi.org/10.1056/nejmra1110265openalex-snapshot
Dengue
inferredcites →https://doi.org/10.1086/315215openalex-snapshot
Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity
inferredcites →https://doi.org/10.1086/427780openalex-snapshot
rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers
inferredcites →https://doi.org/10.1086/500949openalex-snapshot
Vascular Leakage in Severe Dengue Virus Infections: A Potential Role for the Nonstructural Viral Protein NS1 and Complement
inferredcites →https://doi.org/10.1086/649916openalex-snapshot
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
inferredcites →https://doi.org/10.1089/vim.2006.19.10openalex-snapshot
Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics
inferredcites →https://doi.org/10.1093/infdis/jiq059openalex-snapshot
Heterotypic Dengue Infection with Live Attenuated Monotypic Dengue Virus Vaccines: Implications for Vaccination of Populations in Areas Where Dengue Is Endemic
inferredcites →https://doi.org/10.1093/infdis/jis936openalex-snapshot
A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
inferredcites →https://doi.org/10.1093/infdis/jiu061openalex-snapshot
Dengue Human Infection Model: Introduction
inferredcites →https://doi.org/10.1111/j.1749-6632.2009.05052.xopenalex-snapshot
Antibodies Determine Virulence in Dengue
inferredcites →https://doi.org/10.1126/science.101.2634.640openalex-snapshot
Production of Immunity to Dengue with Virus Modified by Propagation in Mice
inferredcites →https://doi.org/10.1128/cmr.11.3.480openalex-snapshot
Dengue and Dengue Hemorrhagic Fever
inferredcites →https://doi.org/10.1371/journal.pntd.0000890openalex-snapshot
Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards
inferredcites →https://doi.org/10.1371/journal.pntd.0001267openalex-snapshot
A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial
inferredcites →https://doi.org/10.1371/journal.pntd.0001742openalex-snapshot
Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans
inferredcites →https://doi.org/10.1371/journal.pntd.0001760openalex-snapshot
Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus
inferredcites →https://doi.org/10.1371/journal.pntd.0002127openalex-snapshot
Will Dengue Vaccines Be Used in the Public Sector and if so, How? Findings from an 8-country Survey of Policymakers and Opinion Leaders
inferredcites →https://doi.org/10.1586/14760584.2013.815412openalex-snapshot
Dengue vaccines: recent developments, ongoing challenges and current candidates
inferredcites →https://doi.org/10.3390/v3122374openalex-snapshot
The Human Antibody Response to Dengue Virus Infection
inferredcites →https://doi.org/10.4049/jimmunol.173.11.6921openalex-snapshot
Platelet-Activating Factor and Kinin-Dependent Vascular Leakage as a Novel Functional Activity of the Soluble Terminal Complement Complex
inferredcites →https://doi.org/10.4161/hv.2.4.2944openalex-snapshot
The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers
inferredcites →https://doi.org/10.4161/hv.2.6.3494openalex-snapshot
rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults
inferredcites →https://doi.org/10.4269/ajtmh.1952.1.30openalex-snapshot
Research on Dengue during World War II
inferredcites →https://doi.org/10.4269/ajtmh.1997.56.566openalex-snapshot
Risk Factors in Dengue Shock Syndrome
inferredcites →https://doi.org/10.4269/ajtmh.2001.65.405openalex-snapshot
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
inferredcites →https://doi.org/10.4269/ajtmh.2001.65.414openalex-snapshot
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
inferredcites →https://doi.org/10.4269/ajtmh.2008.79.678openalex-snapshot
Phase I Clinical Evaluation of rDEN4Δ30-200,201: A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity
inferredcites →https://doi.org/10.4269/ajtmh.2009.09-0131openalex-snapshot
Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4Δ30-4995 in Healthy Adult Volunteers
inferredcites →https://doi.org/10.4269/ajtmh.2011.10-0521openalex-snapshot
Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment
inferredcites →https://doi.org/10.4269/ajtmh.2012.12-0361openalex-snapshot
A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3574666openalex-extracted
Stimulation of B Cell Immunity in Flavivirus-Naïve Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
inferred← citeshttps://doi.org/10.2139/ssrn.4113517openalex-extracted
Immune Metabolic Interplay Drives the Protective Antibody Response Pre-Vaccination with Dengue Virus Vaccine
inferred← citeshttps://doi.org/10.2139/ssrn.4951803openalex-extracted
Optimization for the Production of a Dengue Live-Attenuated Quadrivalent Vaccine in Vero Cells Grown on Microcarriers
inferred← citeshttps://doi.org/10.1002/ana.25588openalex-snapshot
Chronic Dengue Virus Panencephalitis in a Patient with Progressive Dementia with Extrapyramidal Features
inferred← citeshttps://doi.org/10.1002/rmv.2101openalex-snapshot
Dengue: Status of current and under‐development vaccines
inferred← citeshttps://doi.org/10.1007/82_2025_294openalex-snapshot
Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges
inferred← citeshttps://doi.org/10.1007/82_2025_312openalex-snapshot
T Cell Responses During Dengue Infection
inferred← citeshttps://doi.org/10.1007/82_2025_320openalex-snapshot
Dengue Vaccines
inferred← citeshttps://doi.org/10.1007/978-1-0716-3533-9_14openalex-snapshot
Reverse Genetics of Dengue Virus
inferred← citeshttps://doi.org/10.1007/978-3-319-50890-0_6openalex-snapshot
Chikungunya Virus and Zika Virus Expansion: An Imitation of Dengue Virus
inferred← citeshttps://doi.org/10.1007/978-3-319-94075-5_11openalex-snapshot
Mosquito-Borne Diseases: Prevention Is the Cure for Dengue, Chikungunya and Zika Viruses
inferred← citeshttps://doi.org/10.1007/s00103-019-03060-3openalex-snapshot
Dengue vaccine development: status and future
inferred← citeshttps://doi.org/10.1007/s00253-015-6973-7openalex-snapshot
Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences
inferred← citeshttps://doi.org/10.1007/s00430-021-00700-xopenalex-snapshot
Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine
inferred← citeshttps://doi.org/10.1007/s00430-021-00726-1openalex-snapshot
Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics
inferred← citeshttps://doi.org/10.1007/s00705-018-3784-zopenalex-snapshot
Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections
inferred← citeshttps://doi.org/10.1007/s00705-025-06314-5openalex-snapshot
Arboviruses: the hidden danger of the tropics
inferred← citeshttps://doi.org/10.1007/s12013-023-01175-8openalex-snapshot
Computer-aided Affinity Enhancement of a Cross-reactive Antibody against Dengue Virus Envelope Domain III
inferred← citeshttps://doi.org/10.1007/s12098-022-04394-8openalex-snapshot
Management of Dengue: An Updated Review
inferred← citeshttps://doi.org/10.1007/s12275-022-1625-yopenalex-snapshot
Current status and perspectives on vaccine development against dengue virus infection
inferred← citeshttps://doi.org/10.1007/s40259-021-00495-6openalex-snapshot
Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development
inferred← citeshttps://doi.org/10.1007/s40259-022-00531-zopenalex-snapshot
Dengue Vaccines: An Update
inferred← citeshttps://doi.org/10.1007/s40506-023-00263-wopenalex-snapshot
Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines
inferred← citeshttps://doi.org/10.1016/b978-0-12-811865-8.00011-8openalex-snapshot
Chikungunya and Zika Virus Vaccines
inferred← citeshttps://doi.org/10.1016/b978-0-323-35761-6.00017-1openalex-snapshot
Dengue Vaccines
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00019-0openalex-snapshot
Dengue Vaccines
inferred← citeshttps://doi.org/10.1016/b978-0-323-82763-8.00184-9openalex-snapshot
Dengue, Dengue Hemorrhagic Fever, and Severe Dengue
inferred← citeshttps://doi.org/10.1016/j.actatropica.2026.108076openalex-snapshot
Evaluating the safety and efficacy of dengue vaccines: A comprehensive systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.apjtm.2017.03.003openalex-snapshot
Towards development of a universal dengue vaccine – How close are we?
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.112304openalex-snapshot
Targets and strategies for vaccine development against dengue viruses
inferred← citeshttps://doi.org/10.1016/j.cell.2015.07.005openalex-snapshot
Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control
inferred← citeshttps://doi.org/10.1016/j.celrep.2020.108226openalex-snapshot
Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114370openalex-snapshot
A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine
inferred← citeshttps://doi.org/10.1016/j.clinthera.2017.07.001openalex-snapshot
Progress and Works in Progress: Update on Flavivirus Vaccine Development
inferred← citeshttps://doi.org/10.1016/j.coviro.2017.04.002openalex-snapshot
Recent advances in human flavivirus vaccines
inferred← citeshttps://doi.org/10.1016/j.coviro.2020.09.004openalex-snapshot
Dengue vaccine development by the year 2020: challenges and prospects
inferred← citeshttps://doi.org/10.1016/j.coviro.2020.09.005openalex-snapshot
Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005
inferred← citeshttps://doi.org/10.1016/j.ebiom.2019.02.060openalex-snapshot
Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model
inferred← citeshttps://doi.org/10.1016/j.heliyon.2020.e04506openalex-snapshot
Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2023.123630openalex-snapshot
In situ process analytical technology for real time viable cell density and cell viability during live-virus vaccine production
inferred← citeshttps://doi.org/10.1016/j.imj.2021.12.003openalex-snapshot
Host immunity and vaccine development against Dengue virus
inferred← citeshttps://doi.org/10.1016/j.jid.2024.11.015openalex-snapshot
Localized Inflammation in Dengue Vaccine–Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome
inferred← citeshttps://doi.org/10.1016/j.jiph.2026.103232openalex-snapshot
Dengue and chikungunya interface in South and Southeast Asia: Epidemiology, challenges and future directions
inferred← citeshttps://doi.org/10.1016/j.jmb.2016.04.024openalex-snapshot
Dengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika Virus
inferred← citeshttps://doi.org/10.1016/j.jvacx.2022.100142openalex-snapshot
Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
inferred← citeshttps://doi.org/10.1016/j.jvacx.2024.100604openalex-snapshot
Current status of the development of dengue vaccines
inferred← citeshttps://doi.org/10.1016/j.jvacx.2025.100658openalex-snapshot
Optimization for the production of a dengue live-attenuated Quadrivalent vaccine in Vero cells grown on microcarriers
inferred← citeshttps://doi.org/10.1016/j.lmd.2025.100042openalex-snapshot
Rosmarinic acid and dengue virus: Computational insights into antiviral potential
inferred← citeshttps://doi.org/10.1016/j.microb.2025.100387openalex-snapshot
Designing of a novel and potential multi-epitope-based vaccine using NS5 protein of dengue virus targeting all serotypes from India: An immunoinformatic approach
inferred← citeshttps://doi.org/10.1016/j.onehlt.2023.100565openalex-snapshot
Novel approaches for the rapid development of rationally designed arbovirus vaccines
inferred← citeshttps://doi.org/10.1016/j.tmaid.2016.06.005openalex-snapshot
Dengue vaccines: Are they safe for travelers?
inferred← citeshttps://doi.org/10.1016/j.vaccine.2015.05.010openalex-snapshot
The dengue vaccine pipeline: Implications for the future of dengue control
inferred← citeshttps://doi.org/10.1016/j.vaccine.2015.09.052openalex-snapshot
Dengue human infection models to advance dengue vaccine development
inferred← citeshttps://doi.org/10.1016/j.vaccine.2015.09.113openalex-snapshot
WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development
inferred← citeshttps://doi.org/10.1016/j.vaccine.2015.12.073openalex-snapshot
Status of vaccine research and development of vaccines for dengue
inferred← citeshttps://doi.org/10.1016/j.vaccine.2016.03.108openalex-snapshot
Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates
inferred← citeshttps://doi.org/10.1016/j.vaccine.2017.07.045openalex-snapshot
Immune correlates of protection for dengue: State of the art and research agenda
inferred← citeshttps://doi.org/10.1016/j.vaccine.2017.09.089openalex-snapshot
Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.02.062openalex-snapshot
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.03.055openalex-snapshot
Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.08.021openalex-snapshot
Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.02.070openalex-snapshot
A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.09.007openalex-snapshot
‘Mix and Match’ vaccination: Is dengue next?
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.07.045openalex-snapshot
A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127313openalex-snapshot
A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults
inferred← citeshttps://doi.org/10.1016/j.vaccine.2026.128599openalex-snapshot
Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk
inferred← citeshttps://doi.org/10.1016/j.virs.2022.07.003openalex-snapshot
A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice
inferred← citeshttps://doi.org/10.1016/j.virs.2026.01.001openalex-snapshot
Current status of dengue fever epidemics and vaccine development
inferred← citeshttps://doi.org/10.1016/j.xcrm.2020.100155openalex-snapshot
Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
inferred← citeshttps://doi.org/10.1016/s1473-3099(16)30471-6openalex-snapshot
Prevention and control of dengue—the light at the end of the tunnel
inferred← citeshttps://doi.org/10.1016/s1473-3099(17)30362-6openalex-snapshot
Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue
inferred← citeshttps://doi.org/10.1016/s1473-3099(20)30023-2openalex-snapshot
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial
inferred← citeshttps://doi.org/10.1016/s1473-3099(20)30082-7openalex-snapshot
Balanced immunity is key for a successful dengue vaccine
inferred← citeshttps://doi.org/10.1016/s1473-3099(20)30767-2openalex-snapshot
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study
inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00520-0openalex-snapshot
Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial
inferred← citeshttps://doi.org/10.1016/s1473-3099(24)00376-1openalex-snapshot
Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil
inferred← citeshttps://doi.org/10.1016/s2352-4642(19)30205-6openalex-snapshot
Dengue infection and advances in dengue vaccines for children
inferred← citeshttps://doi.org/10.1038/cmi.2015.76openalex-snapshot
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine
inferred← citeshttps://doi.org/10.1038/nrdp.2016.55openalex-snapshot
Dengue infection
inferred← citeshttps://doi.org/10.1038/nri3916openalex-snapshot
New insights into the immunopathology and control of dengue virus infection
inferred← citeshttps://doi.org/10.1038/s41467-021-21384-0openalex-snapshot
A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
inferred← citeshttps://doi.org/10.1038/s41467-021-22930-6openalex-snapshot
Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model
inferred← citeshttps://doi.org/10.1038/s41541-021-00339-yopenalex-snapshot
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
inferred← citeshttps://doi.org/10.1038/s41541-025-01204-yopenalex-snapshot
Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults
inferred← citeshttps://doi.org/10.1038/s41541-026-01400-4openalex-snapshot
From promise to pitfalls: immunological lessons from dengue vaccines and their implications
inferred← citeshttps://doi.org/10.1038/s41598-017-04767-6openalex-snapshot
In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers
inferred← citeshttps://doi.org/10.1038/s41598-017-17355-5openalex-snapshot
Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4
inferred← citeshttps://doi.org/10.1038/s41598-018-26800-yopenalex-snapshot
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
inferred← citeshttps://doi.org/10.1055/s-0036-1592070openalex-snapshot
Vaccine Development for Zika Virus—Timelines and Strategies
inferred← citeshttps://doi.org/10.1056/nejmoa2301790openalex-snapshot
Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults
inferred← citeshttps://doi.org/10.1073/pnas.1903496117openalex-snapshot
Designing effective control of dengue with combined interventions
inferred← citeshttps://doi.org/10.1080/14712598.2017.1356284openalex-snapshot
Working towards dengue as a vaccine-preventable disease: challenges and opportunities
inferred← citeshttps://doi.org/10.1080/14760584.2017.1335201openalex-snapshot
A recombinant live attenuated tetravalent vaccine for the prevention of dengue
inferred← citeshttps://doi.org/10.1080/14787210.2021.1949983openalex-snapshot
Dengue vaccine: an update
inferred← citeshttps://doi.org/10.1080/15321819.2016.1269338openalex-snapshot
A comparison of nanoparticle-antibody conjugation strategies in sandwich immunoassays
inferred← citeshttps://doi.org/10.1080/17460441.2020.1811675openalex-snapshot
An update on dengue vaccine development, challenges, and future perspectives
inferred← citeshttps://doi.org/10.1080/17460441.2025.2601880openalex-snapshot
E protein inhibitors and host-directed therapies in dengue virus infection: perspectives on combination and complementary antiviral strategies
inferred← citeshttps://doi.org/10.1080/21645515.2016.1261770openalex-snapshot
Vaccines licensed and in clinical trials for the prevention of dengue
inferred← citeshttps://doi.org/10.1080/21645515.2021.1884473openalex-snapshot
Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in ex vivo and in vivo models
inferred← citeshttps://doi.org/10.1080/21645515.2022.2046960openalex-snapshot
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults
inferred← citeshttps://doi.org/10.1080/21645515.2024.2337985openalex-snapshot
A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health
inferred← citeshttps://doi.org/10.1093/cid/ciag349openalex-snapshot
Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial
inferred← citeshttps://doi.org/10.1093/femspd/ftz003openalex-snapshot
Focused dengue vaccine development: outwitting nature's design
inferred← citeshttps://doi.org/10.1093/infdis/jiag396openalex-snapshot
The Power of Public Science: Lessons From TV003 and Butantan-DV
inferred← citeshttps://doi.org/10.1093/infdis/jiv086openalex-snapshot
A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate
inferred← citeshttps://doi.org/10.1093/infdis/jiw067openalex-snapshot
A 12-Month–Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response
inferred← citeshttps://doi.org/10.1093/jpids/piy140openalex-snapshot
Dengue Vaccine, A Double-Edged Sword
inferred← citeshttps://doi.org/10.1093/jtm/tay153openalex-snapshot
What is the prospect of a safe and effective dengue vaccine for travellers?
inferred← citeshttps://doi.org/10.1097/qco.0000000000000871openalex-snapshot
Dengue vaccine development: challenges and prospects
inferred← citeshttps://doi.org/10.1099/jgv.0.000669openalex-snapshot
Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients
inferred← citeshttps://doi.org/10.1099/jgv.0.001271openalex-snapshot
A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine
inferred← citeshttps://doi.org/10.1099/jgv.0.001831openalex-snapshot
Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art
inferred← citeshttps://doi.org/10.1101/2021.01.05.425517openalex-snapshot
A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity
inferred← citeshttps://doi.org/10.1101/cshperspect.a028811openalex-snapshot
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?
inferred← citeshttps://doi.org/10.1101/cshperspect.a030700openalex-snapshot
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?
inferred← citeshttps://doi.org/10.1126/science.aaf9590openalex-snapshot
Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
inferred← citeshttps://doi.org/10.1126/scitranslmed.aaf1517openalex-snapshot
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
inferred← citeshttps://doi.org/10.1126/scitranslmed.abo5019openalex-snapshot
Evolution of inflammation and immunity in a dengue virus 1 human infection model
inferred← citeshttps://doi.org/10.1126/scitranslmed.adh3067openalex-snapshot
Insights into dengue immunity from vaccine trials
inferred← citeshttps://doi.org/10.1128/9781555819439.ch53openalex-snapshot
Arthropod-Borne Flaviviruses
inferred← citeshttps://doi.org/10.1128/cmr.00008-21openalex-snapshot
Controlled Human Infection Models To Accelerate Vaccine Development
inferred← citeshttps://doi.org/10.1128/jvi.00089-20openalex-snapshot
T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species
inferred← citeshttps://doi.org/10.1128/jvi.00100-23openalex-snapshot
Subgenomic flavivirus RNA as key target for live-attenuated vaccine development
inferred← citeshttps://doi.org/10.1128/jvi.00963-23openalex-snapshot
Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
inferred← citeshttps://doi.org/10.1128/jvi.01023-18openalex-snapshot
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
inferred← citeshttps://doi.org/10.1128/jvi.01469-17openalex-snapshot
Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans
inferred← citeshttps://doi.org/10.1128/jvi.02133-16openalex-snapshot
Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain
inferred← citeshttps://doi.org/10.1128/jvi.02482-20openalex-snapshot
A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses
inferred← citeshttps://doi.org/10.1128/mbio.01316-15openalex-snapshot
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection
inferred← citeshttps://doi.org/10.1128/msphere.00497-26openalex-snapshot
Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection
inferred← citeshttps://doi.org/10.1136/bmj.l5710openalex-snapshot
Is Dengvaxia a useful vaccine for dengue endemic areas?
inferred← citeshttps://doi.org/10.1139/cjm-2020-0572openalex-snapshot
Dengue virus: epidemiology, biology, and disease aetiology
inferred← citeshttps://doi.org/10.1146/annurev-med-091014-090848openalex-snapshot
Vaccination Against Dengue: Challenges and Current Developments
inferred← citeshttps://doi.org/10.11606/d.42.2016.tde-17112016-111237openalex-snapshot
Desenvolvimento de formulações vacinais contra a dengue baseadas na proteína não estrutural 1 (NS1) administrada pela via intradérmica.
inferred← citeshttps://doi.org/10.11606/d.42.2017.tde-14072017-112246openalex-snapshot
Desenvolvimento de modelo experimental de infecção pelo vírus da dengue em camundongos.
inferred← citeshttps://doi.org/10.1172/jci.insight.124588openalex-snapshot
Human antibody response to Zika targets type-specific quaternary structure epitopes
inferred← citeshttps://doi.org/10.1172/jci.insight.94500openalex-snapshot
Dengue vaccine–induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies
inferred← citeshttps://doi.org/10.1172/jci173328openalex-snapshot
TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies
inferred← citeshttps://doi.org/10.1177/0976500x231204401openalex-snapshot
Dengue Virus: Molecular Biology and Recent Developments in Control Strategies, Prevention, Management, and Therapeutics
inferred← citeshttps://doi.org/10.1177/20499361231167274openalex-snapshot
A dengue vaccine whirlwind update
inferred← citeshttps://doi.org/10.1182/blood-2018-09-873984openalex-snapshot
Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3
inferred← citeshttps://doi.org/10.1186/s12879-023-08299-5openalex-snapshot
Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
inferred← citeshttps://doi.org/10.1186/s12879-026-13364-wopenalex-snapshot
Spatiotemporal dynamics of dengue: a town level study in Guangdong, China
inferred← citeshttps://doi.org/10.12688/f1000research.19197.1openalex-snapshot
Recent advances in understanding dengue
inferred← citeshttps://doi.org/10.12688/f1000research.6233.1openalex-snapshot
Recent advances in understanding dengue
inferred← citeshttps://doi.org/10.12932/ap-100518-0309openalex-snapshot
Dengue vaccine: Global development update
inferred← citeshttps://doi.org/10.1371/journal.pmed.1002182openalex-snapshot
The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits
inferred← citeshttps://doi.org/10.1371/journal.pntd.0005584openalex-snapshot
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
inferred← citeshttps://doi.org/10.1371/journal.pntd.0006862openalex-snapshot
Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus
inferred← citeshttps://doi.org/10.1586/14760584.2016.1106318openalex-snapshot
Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?
inferred← citeshttps://doi.org/10.1586/14760584.2016.1115727openalex-snapshot
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
inferred← citeshttps://doi.org/10.1586/14760584.2016.1116949openalex-snapshot
Immune correlates for dengue vaccine development
inferred← citeshttps://doi.org/10.1586/14760584.2016.1121814openalex-snapshot
Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development
inferred← citeshttps://doi.org/10.1586/14760584.2016.1128328openalex-snapshot
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone
inferred← citeshttps://doi.org/10.17352/apm.000009openalex-snapshot
Reducing the Global Burden of Dengue: Steps toward Preventive Methods
inferred← citeshttps://doi.org/10.18378/rebes.v14i3.10874openalex-snapshot
Desafios no controle da dengue em países tropicais: avanços nas vacinas e perspectivas
inferred← citeshttps://doi.org/10.20473/fmi.v57i4.21741openalex-snapshot
Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV; TDV (TAK-003) and TV003/TV005
inferred← citeshttps://doi.org/10.2174/1381612823666170913163904openalex-snapshot
Development of Peptide Vaccines in Dengue
inferred← citeshttps://doi.org/10.2174/1389450120666190724145937openalex-snapshot
A Multi-Perspective Review on Dengue Research
inferred← citeshttps://doi.org/10.21767/amj.2018.3451openalex-snapshot
Development of dengue vaccines
inferred← citeshttps://doi.org/10.22207/jpam.20.3.34openalex-snapshot
Dengue Fever in India at a Crossroads: Spatiotemporal Trends, Climate Change, and Vaccine Challenges in the Post-COVID Era
inferred← citeshttps://doi.org/10.23937/2474-3658/1510015openalex-snapshot
Dengue Fever: Historical Perspective and the Global Response
inferred← citeshttps://doi.org/10.25259/ijmr_1987_2026openalex-snapshot
Dengue vaccines and serotype complexity: Why India needs a calibrated strategy
inferred← citeshttps://doi.org/10.32657/10220/46782openalex-snapshot
Structural and biochemical characterization of non-structural protein 3 from flavivirus
inferred← citeshttps://doi.org/10.3329/jom.v25i1.70361openalex-snapshot
The Quest for an Effective Dengue Vaccine: Hope or Hype
inferred← citeshttps://doi.org/10.3389/fcimb.2017.00336openalex-snapshot
Prevention and Control Strategies to Counter Dengue Virus Infection
inferred← citeshttps://doi.org/10.3389/fimmu.2019.01956openalex-snapshot
Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?
inferred← citeshttps://doi.org/10.3389/fimmu.2019.02125openalex-snapshot
Human T Cell Response to Dengue Virus Infection
inferred← citeshttps://doi.org/10.3389/fimmu.2020.00479openalex-snapshot
Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01055openalex-snapshot
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01252openalex-snapshot
Anti-dengue Vaccines: From Development to Clinical Trials
inferred← citeshttps://doi.org/10.3389/fimmu.2022.840104openalex-snapshot
Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
inferred← citeshttps://doi.org/10.3389/fimmu.2022.908398openalex-snapshot
Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1362780openalex-snapshot
Approaches of dengue control: vaccine strategies and future aspects
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1809605openalex-snapshot
Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms
inferred← citeshttps://doi.org/10.3389/fmicb.2021.744233openalex-snapshot
Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection
inferred← citeshttps://doi.org/10.3389/fmicb.2024.1423044openalex-snapshot
An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh–A perspective
inferred← citeshttps://doi.org/10.3390/idr17050117openalex-snapshot
State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature
inferred← citeshttps://doi.org/10.3390/molecules26226768openalex-snapshot
Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
inferred← citeshttps://doi.org/10.3390/pathogens9060470openalex-snapshot
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
inferred← citeshttps://doi.org/10.3390/v11090823openalex-snapshot
Twenty Years of Progress Toward West Nile Virus Vaccine Development
inferred← citeshttps://doi.org/10.3390/v12080829openalex-snapshot
Dengue: A Minireview
inferred← citeshttps://doi.org/10.3390/v17030382openalex-snapshot
Vaccines Against Urban Epidemic Arboviruses: The State of the Art
inferred← citeshttps://doi.org/10.3390/v9050097openalex-snapshot
Historical Perspectives on Flavivirus Research
inferred← citeshttps://doi.org/10.3390/vaccines10040612openalex-snapshot
Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity
inferred← citeshttps://doi.org/10.3390/vaccines10111940openalex-snapshot
Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach
inferred← citeshttps://doi.org/10.3390/vaccines12080913openalex-snapshot
The Urgent Need for Dengue Vaccination: Combating an Escalating Public Health Crisis in Pakistan
inferred← citeshttps://doi.org/10.3390/vaccines13050449openalex-snapshot
From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity
inferred← citeshttps://doi.org/10.3390/vaccines13050532openalex-snapshot
Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue
inferred← citeshttps://doi.org/10.3390/vaccines8010063openalex-snapshot
A Review on Dengue Vaccine Development
inferred← citeshttps://doi.org/10.3390/vaccines8030492openalex-snapshot
Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli
inferred← citeshttps://doi.org/10.37871/jbres1894openalex-snapshot
The Recombinant NS3 Protein a Potential Antigen for Dengue Vaccine Development
inferred← citeshttps://doi.org/10.4049/jimmunol.1601523openalex-snapshot
Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection
inferred← citeshttps://doi.org/10.4103/0971-5916.193300openalex-snapshot
A novel indirect ELISA for diagnosis of dengue fever
inferred← citeshttps://doi.org/10.4269/ajtmh.16-0222openalex-snapshot
Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge
inferred← citeshttps://doi.org/10.4269/ajtmh.20-0042openalex-snapshot
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial
inferred← citeshttps://doi.org/10.52226/revista.v31i113.294openalex-snapshot
Documento sobre el uso de vacunas para la prevencion del dengue
inferred← citeshttps://doi.org/10.70675/84773006z54bez4906zb40dzc0f24aaeb05aopenalex-snapshot
Contribution à la caractérisation moléculaire et cellulaire des chimères YF-17D / Dengue dans le cadre du développement préclinique du vaccin Dengvaxia®
inferred← citeshttps://doi.org/10.70675/b905723bz7dc8z4eb1za12bz38505b56865dopenalex-snapshot
Dengue and Zika viral-like particle-based vaccines
inferred← citeshttps://doi.org/10.70675/bf65601az00eaz4c84za2a2z0ec518b23c7copenalex-snapshot
Diagnostic de la dengue : trois solutions pour améliorer la prise en charge des patients et faciliter les études épidémiologiques
showing the first 200 of 205
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.